GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (GREY:PSTTF) » Definitions » Institutional Ownership

Prescient Therapeutics (Prescient Therapeutics) Institutional Ownership : 0.17% (As of May. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Prescient Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Prescient Therapeutics's institutional ownership is 0.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Prescient Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Prescient Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Prescient Therapeutics Institutional Ownership Historical Data

The historical data trend for Prescient Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Institutional Ownership Chart

Prescient Therapeutics Historical Data

The historical data trend for Prescient Therapeutics can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 0.20 0.18 0.18 0.18 0.18 0.18 0.18 0.17 0.17 0.17

Prescient Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Prescient Therapeutics (Prescient Therapeutics) Business Description

Traded in Other Exchanges
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.